Hepatocyte growth factor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-01. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
Fermentation begins once the growth medium is inoculated with the organism of interest. Growth of the inoculum does not occur immediately. This is the period of adaptation, called the lag phase. Following the lag phase, the rate of growth of the organism steadily increases, for a certain period—this period is the log or exponential phase. After a phase of exponential growth, the rate of growth slows down, due to the continuously falling concentrations of nutrients and/or a continuously increasing (accumulating) concentrations of toxic substances. This phase, where the increase of the rate of growth is checked, is the deceleration phase. After the deceleration phase, growth ceases and the culture enters a stationary phase or a steady state. The biomass remains constant, except when certain accumulated chemicals in the culture chemically break down the cells in a process called chemolysis. Unless other microorganisms contaminate the culture, the chemical constitution remains unchanged. If all of the nutrients in the medium are consumed, or if the concentration of toxins is too great, the cells may become senescent and begin to die off. The total amount of biomass may not decrease, but the number of viable organisms will decrease.
Serbian police and VJ units attacked KLA outposts, attempting to destroy them, as KLA units attempted to avoid direct confrontation and use terrorist attacks, including bombings and ambushes, to weaken Yugoslav control. Although unable to gain a strategic advantage, Yugoslav Army units found themselves in a tactical advantage against KLA units which lacked proper training. VJ units themselves lacked morale, and attacks were often directed against civilian targets rather than military targets. 863,000 Albanian civilians were forcibly expelled between March and June 1999 from Kosovo. 169,824 Serb and Romani civilians were estimated by the UNHCR's Belgrade office to have fled from Kosovo-Metohija to either Serbia proper, the Autonomous Province of Vojvodina, or the constituent Republic of Montenegro by 20 June 1999. Out of 10,317 civilians, 8,676 Albanians, 1,196 Serbs and 445 Roma, Bosniaks, Montenegrins and others were killed or went missing in connection with the war between 1 January 1998 - 31 December 2000. The Serbian government attributed 1,953 Serbian, 361 Albanian and 266 other civilian deaths or disappearances from 1 January 1998 - 1 November 2001 to "Albanian terrorism in Kosovo-Metohija". The international community was quick to respond, issuing a peace proposal to Yugoslavia in 1999. The agreement was seen as essentially an ultimatum by NATO to Yugoslavia, and this was rejected by the Yugoslav government.
Upstream of GPX4, depletion of GSH by inhibiting GSH biosynthesis also induces ferroptosis. Work from Kojin Therapeutics and Ono Pharmaceutical has demonstrated that inhibition of glutamate-cysteine ligase (GCL), the rate-limiting enzyme in GSH biosynthesis, induces ferroptosis in cancer cell lines. GCL also suppresses ferroptosis through a GSH-independent mechanisms such as limiting glutamate accumulation. Buthionine sulfoximine (BSO) has been commonly used as a tool compound to inhibit GCL, though BSO is relatively low potency. Accordingly, analogues have been reported that show improved potency and pharmacological properties that may be used in in vivo studies. FSP1 inhibition is generally not sufficient to induce ferroptosis but FSP1 inhibitors such as iFSP1 (targeting the CoQ10 binding site) and viFSP1 (versatile inhibitor of FSP1; targeting the NAD(P)H binding pocket) have been explored as ferroptosis sensitizers. iFSP1 is not usable in rodent models, though viFSP1 is species-independent. FSEN1 is an uncompetitive inhibitor of FSP1 that binds to the FSP1–NADH–CoQ complex. 3-Phenylquinazolines (represented by icFSP1) do not competitively inhibit FSP1 enzymatic activity but rather trigger phase separation of FSP1 followed by induction of ferroptosis. Notably, FSP1 activity can compensate for GPX4 loss and suppress ferroptosis in certain contexts.
== Active site and catalytic mechanism == All the proteolytic activity of the asparagine peptide lyases is only self-cleavages, then no further peptidase activity occurs. The main residue of the active site is the asparagine and there are other residues involved in the catalytic mechanism, which are different between the different families of asparagine peptide lyases. The cleavage mechanism consists in the cyclization of the asparagine, assisted by other active site residues. In certain conditions, the asparagine cyclic structure nucleophilically attacks its C-terminal peptide bond to the main chain forming a new bond to create a stable succinimide, cleaving itself from the main chain and consequently releasing the two halves of the product.
Sources: en.wikipedia.org
== External links == Tobacco Etch Virus (Pepper Diseases) Archived 2010-08-27 at the Wayback Machine Tobacco Etch Virus (Tomato Diseases) Archived 2011-07-16 at the Wayback Machine Tobacco Etch Virus (DAS-ELISA) Archived 2016-04-17 at the Wayback Machine ICTVdB - The Universal Virus Database: Tobacco etch virus Family Groups - The Baltimore Method Archived 2000-01-15 at the Wayback Machine Descriptions of Plant Viruses (DPV)
== Chemical synthesis and manipulation of carbohydrates == Carbohydrate synthesis is a sub-field of organic chemistry concerned specifically with the generation of natural and unnatural carbohydrate structures. Carbohydrate chemistry is a large and economically important branch of organic chemistry. This can include the synthesis of monosaccharide residues or structures containing more than one monosaccharide, known as oligosaccharides. Selective formation of glycosidic linkages and selective reactions of hydroxyl groups are very important, and the usage of protecting groups is extensive. Some of the main organic reactions that involve carbohydrates are:
Nonetheless, ECB Vice President Luis de Guindos stated that central bank liquidity swap lines between the Federal Reserve and the ECB remained "business as usual". International Monetary Fund Director Kristalina Georgieva also spoke in defense of Powell and the Federal Reserve's independence given the role of the United States dollar as the world's reserve currency.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.